Author: Fiona Craig

  • Informa to Acquire Clarion for £2.24 Billion and Review Taylor & Francis Separation

    Informa to Acquire Clarion for £2.24 Billion and Review Taylor & Francis Separation

    Informa (LSE:INF) has agreed to acquire events organiser Clarion from Blackstone for an enterprise value of £2.24 billion, or approximately $3 billion, as the group also begins a formal review of separating its Taylor & Francis academic publishing business.

    The transaction values Clarion at 11.1 times expected 2027 EBITDA. Informa said the multiple would fall to approximately nine times after including £50 million of anticipated annual run-rate cost savings.

    The company expects the acquisition to increase adjusted diluted earnings per share by a mid-single-digit percentage in 2027 and generate a post-tax return on invested capital of more than 10% by 2029.

    Clarion Expected to Generate More Than £575 Million of Revenue

    Clarion operates more than 100 business-to-business event brands, including the IFA consumer electronics exhibition in Germany, DSEI defence exhibition and ICE gaming event in Barcelona.

    The business is expected to generate more than £575 million of revenue in 2027, with an adjusted operating margin above 30%.

    Informa said the combination would create the largest UK-listed B2B events operator, with group revenue exceeding $6 billion and underlying growth of approximately 7%.

    In addition to the planned £50 million of annual cost savings, Informa has identified £25 million of additional operating profit from potential revenue synergies by 2029.

    Informa Plans £940 Million Equity Raise

    Informa intends to fund the acquisition through acquisition financing and an equity raise of approximately £940 million, equivalent to around 9% of its existing share capital.

    The equity financing will comprise an institutional placing and a retail offer. Informa will pause its existing share buyback as part of the transaction.

    The company expects net debt to EBITDA to remain below three times at year-end and decline to below 2.5 times by the end of 2027.

    Completion of the Clarion acquisition is expected late in the fourth quarter, subject to regulatory approvals.

    Taylor & Francis Enters Formal Separation Review

    Alongside the acquisition, Informa has launched a formal review of a potential separation of Taylor & Francis from the group.

    The academic publishing business is approaching $1 billion in annual revenue and is growing at approximately 4% a year. Informa expects to report the outcome of the review alongside its full-year results in March 2027.

    The company has not specified whether a separation would take the form of a sale, spin-off or another transaction.

    Chief Executive Stephen Carter said: “With Taylor & Francis approaching $1bn in revenue, growing at 4%± and with its Open Research capabilities firmly established, we believe it will now benefit from greater flexibility and freedom through the next phase of its development, as Informa further expands the depth and reach of its B2B portfolio.”

    Blackstone acquired Clarion from Providence Equity Partners in 2017 for £600 million.

  • MedPal AI Reports Annualised Revenue Run Rate Above £38 Million

    MedPal AI Reports Annualised Revenue Run Rate Above £38 Million

    MedPal AI (LSE:MPAL) said its group annualised revenue run rate increased to more than £38 million following further growth in September.

    The digital health and pharmacy group generated approximately £3.2 million of revenue during the month and dispensed more than 58,800 prescription items and orders.

    Revenue at its New Health business rose approximately 50% month on month to more than £2.7 million, generated from over 22,600 orders.

    Repeat and Recurring Revenue Exceeds £1 Million

    MedPal said repeat orders, NHS prescriptions and eMARx subscriptions generated more than £1 million of revenue in September, representing around one-third of group revenue.

    The company said these orders generated higher average order values than first-time orders and expects the proportion of repeat and recurring revenue to increase as recently acquired customers reach their reorder dates.

    MedPal is also expanding capacity at Sarus Court using proceeds from its recent £5 million placing. An enlarged GLP-1 production line is expected to increase daily order capacity to 14,000 by the end of October.

    MedPal Seeks Receivables-Backed Financing

    The company said its growth has created additional working capital requirements because payments for medication are made before the receipt of NHS reimbursements and supplier rebates.

    MedPal is in discussions with UK clearing banks regarding a receivables-backed financing facility and also expects changes to supplier credit terms.

    The company said these financing arrangements, if completed, could reduce its reliance on additional equity funding. No agreement on a bank facility has been confirmed in the supplied material.

    Shareholders to Vote on New Equity Authorities

    MedPal is convening a general meeting to seek renewed authority for directors to issue equity securities after existing authorities were used in connection with acquisitions, fees and other share issuances.

    The company has also granted warrants owed to its broker, Clear Capital, some of which have been exercised. MedPal expects to issue the remaining shares associated with the warrants after obtaining the required shareholder authorities.

    Following admission of 3.7 million warrant shares, the company’s issued share capital will comprise 889,949,135 ordinary shares. Each share carries one voting right, and the company holds no shares in treasury.

    Shareholders are being asked to approve the renewed authorities ahead of MedPal’s next annual general meeting, scheduled for March 2027.

    MedPal AI Operations

    MedPal AI operates digital healthcare, pharmacy and software businesses in the UK. These include NHS Distance Selling Pharmacy hubs, the New Health GLP-1 weight-management service, eMARx medication administration software and a pharmacy supply operation serving care homes.

    The group is also developing Juno, an AI health companion built using Anthropic’s Claude, as part of its planned Health OS platform connecting prescribing, dispensing, delivery, medication administration and patient support.

    MedPal’s shares are traded on AIM and Frankfurt.

  • Clarksons Raises 2026 Profit Outlook After Higher August and September Trading

    Clarksons Raises 2026 Profit Outlook After Higher August and September Trading

    Clarkson PLC (LSE:CKN) raised its full-year profit expectations following higher-than-anticipated trading activity during August and September.

    The shipping services group now expects underlying profit before tax for 2026 to be at least £135 million.

    Clarksons said trading during the two-month period benefited from increased volatility across commodity and freight markets amid geopolitical tensions. Freight rates and asset prices reached record levels in some areas, according to the company.

    Broking Revenue Exceeds Expectations

    The group’s Broking division generated revenue significantly above management’s expectations during the period and increased its forward order book.

    Clarksons’ Financial division also completed more transactions than the company had anticipated, contributing to the revised full-year profit outlook.

    The company said its investments in global teams, trading tools and technology supported its ability to operate during periods of increased activity and market volatility.

    The supplied material did not provide the company’s previous underlying pre-tax profit forecast or quantify the increase in its Broking division’s revenue and forward order book.

    Clarkson Operations

    Clarkson provides integrated services to the global shipping and offshore industries, including shipbroking, sector research, logistics and capital markets services.

    Founded in 1852, the group employs more than 2,250 people across over 70 offices. Its shares are listed on the London Stock Exchange’s main market and the company is a constituent of the FTSE 250.

    According to the supplied material, Clarksons has recorded 23 consecutive years of dividend growth.

  • Synectics Expects FY26 Adjusted EBITDA at Top End of Guidance

    Synectics Expects FY26 Adjusted EBITDA at Top End of Guidance

    Synectics (LSE:SNX) expects adjusted EBITDA for the year ending 30 November 2026 to be at the top end of its £3.7 million to £4.1 million guidance range.

    The security and surveillance technology company said full-year revenue is expected to be broadly in line with market forecasts, while improved margins contributed to its anticipated EBITDA performance.

    Synectics attributed the progress in part to changes implemented under its “5P” strategy, which includes simplifying product deployment, developing its partner management activities and applying greater commercial discipline.

    Energy Opportunities Shift Into FY27

    The company said some opportunities within its Energy business, particularly in the Middle East, have moved from FY26 into FY27.

    Synectics said these opportunities remain active within its pipeline rather than having been cancelled.

    The group also reported a backlog of Energy sector work entering FY27 alongside opportunities across other critical security markets.

    Management said commercial, product and operational changes intended to support the company’s growth strategy are increasingly being incorporated across the business.

    The board said it remains confident in the group’s growth prospects for FY27, based on its existing backlog and pipeline of potential work.

    Synectics Operations

    Synectics is an AIM-listed provider of security, surveillance and operational intelligence systems.

    The company’s technology combines security systems and operational data for customers operating in critical security markets, with applications covering the protection of people, property and other assets.

  • Avacta Raises £12.5 Million to Fund Oncology Development

    Avacta Raises £12.5 Million to Fund Oncology Development

    Avacta (LSE:AVCT) has raised £12.5 million through a placing and director-led subscription of new ordinary shares at 68 pence per share.

    The new shares represent approximately 3.9% of Avacta’s existing issued share capital. The company said the proceeds are expected to extend its cash runway into the second quarter of 2027 and support continued clinical development of its pre|CISION-based oncology pipeline.

    Avacta also expects the additional funding to support its position in discussions with potential partners.

    Funding to Support AVA6103 and AVA6207 Programmes

    The company plans to use the proceeds to progress several development milestones across its oncology portfolio.

    Avacta expects to report the first clinical efficacy data for lead candidate AVA6103 during the first half of 2027.

    The company is also targeting the selection of a clinical candidate for AVA6207, its dual-payload programme, during the current quarter. The selected candidate would subsequently progress towards investigational new drug-enabling studies.

    Both programmes use Avacta’s pre|CISION platform, which is designed to activate therapeutic payloads within the tumour microenvironment through fibroblast activation protein, or FAP.

    AIM Trading Resumes Following Fundraise

    Trading in Avacta shares on AIM is resuming following the closure of the company’s capital access window.

    Following admission of the new shares, Avacta’s total issued share capital will increase to 489,712,861 ordinary shares.

    The enlarged share capital will also form the basis for shareholders’ calculations relating to applicable disclosure thresholds.

    Avacta Operations

    Avacta is a clinical-stage life sciences company developing targeted oncology therapies.

    Its pre|CISION platform uses the tumour-associated protease FAP with the aim of concentrating therapeutic payloads within the tumour microenvironment while limiting exposure to healthy tissue.

    The company’s development portfolio includes peptide drug conjugates targeting cancer indications.

  • 80 Mile and Greenland Energy Extend Takeover Deadline to 3 November

    80 Mile and Greenland Energy Extend Takeover Deadline to 3 November

    80 Mile plc (LSE:80M) and Greenland Energy Company (NASDAQ:GLND) have agreed to extend the deadline for Greenland Energy to decide whether to make a firm all-share offer for 80 Mile.

    Under the revised timetable, Greenland Energy has until 5:00 p.m. on 3 November 2026 to either announce a firm intention to make an offer or confirm that it does not intend to proceed, in accordance with the UK Takeover Code.

    The companies said the extension provides additional time to complete confirmatory due diligence and reflects the cross-border nature of the proposed transaction.

    Companies Continue Work on Proposed All-Share Deal

    The boards of 80 Mile and Greenland Energy continue to work on definitive documentation relating to the potential combination.

    Under the proposed structure, 80 Mile shareholders would receive shares in an enlarged Greenland Energy group, maintaining exposure to the combined business through a U.S.-listed company.

    Management of the two companies believes a combination would consolidate their existing partnership in Greenland into a single corporate structure and provide the enlarged group with additional access to capital.

    The companies have also identified potential reductions in duplicated corporate functions and a broader shareholder base as intended features of the proposed transaction.

    However, there is no certainty that Greenland Energy will make a firm offer for 80 Mile or that a transaction will ultimately proceed.

    Takeover Process Continues

    The companies remain subject to applicable regulatory and disclosure requirements while the potential transaction is under consideration.

    The extension moves the previous “put up or shut up” deadline to 3 November, allowing discussions, due diligence and preparation of transaction documentation to continue.

    80 Mile Operations

    80 Mile operates in the mining and natural resources sector, with a focus on projects in Greenland.

    The company has an existing partnership with Greenland Energy Company, which the proposed all-share transaction would bring together within a single U.S.-listed group if completed.

  • Celebrus Technologies Cuts FY27 Guidance After First-Half Revenue Decline

    Celebrus Technologies Cuts FY27 Guidance After First-Half Revenue Decline

    Celebrus Technologies (LSE:CLBS) lowered its full-year 2027 guidance following a review of its sales pipeline, after first-half revenue declined and the company lost a major customer.

    For the six months ended 30 September 2026, total revenue is expected to be approximately $9.2 million, compared with $10.4 million in the corresponding period a year earlier.

    Software revenue increased to around $8.9 million, while lower third-party product sales contributed to the decline in overall revenue.

    Annual recurring revenue fell 2% to $14.7 million following the loss of a major customer.

    Adjusted First-Half Loss Narrows to $1.3 Million

    Celebrus expects to report an adjusted loss before tax of approximately $1.3 million for the first half, compared with the figure supplied by the company indicating a slightly larger loss in the prior-year period.

    The group remained debt-free and ended the period with cash of $22.3 million after dividend payments and share buybacks.

    Management acknowledged execution issues associated with the loss of the customer as well as delays in closing new business.

    The company said it has made changes across its marketing, sales and customer success operations. It has also appointed a new vice president of global services, with a focus on standardising the implementation of more complex projects.

    FY27 Revenue Forecast at $20.0 Million to $20.5 Million

    Following a review of its pipeline, the board now expects FY27 revenue of between $20.0 million and $20.5 million.

    Celebrus also forecasts an adjusted pre-tax loss of between $2.8 million and $3.0 million for the full year.

    The revised forecasts are below previous market expectations, according to the supplied material.

    Celebrus Technologies Operations

    Celebrus Technologies is an AIM-listed data solutions company providing software designed to capture and manage digital customer data and identities in real time.

    Its technology is used for applications including marketing and fraud prevention, with customers operating across more than 30 countries.

  • Telecom Plus Maintains FY27 Profit Guidance as Customer Numbers Rise

    Telecom Plus Maintains FY27 Profit Guidance as Customer Numbers Rise

    Telecom Plus (LSE:TEP) maintained its full-year guidance for adjusted pre-tax profit of between £80 million and £90 million after reporting growth in customer and partner numbers during the first half.

    The company, which operates under the Utility Warehouse brand, said multiservice organic customer numbers were growing at an annualised rate of more than 11%, while total organic customers reached approximately 1.32 million.

    Telecom Plus said the performance reflected growth in its partner network and changes to its multiservice propositions as it progresses its five-year plan.

    Partner Network Expands to More Than 88,000

    Monthly active partner numbers increased by approximately 15%, while the total number of partners rose above 88,000.

    The company also reported record attendance at its sales conference and has introduced incentives including share options and an unlimited mobile offering as part of its efforts to expand the partner network.

    Telecom Plus is preparing a broader brand advertising campaign and continues to focus on increasing the number of services taken by individual customers across its energy, broadband, mobile and insurance products.

    The group also reported progress with its digitalisation and insurance initiatives.

    £40 Million Share Buyback Underway

    Telecom Plus outlined a £40 million share buyback and said additional shareholder distributions are expected to be weighted towards the second half of the financial year.

    The company is also targeting a reduction in leverage over the course of its five-year plan.

    Telecom Plus noted that BT’s acquisition of its broadband platform provider provides additional security around its connectivity arrangements.

    Management continues to target double-digit multiservice customer growth under its five-year strategy, while maintaining its FY27 adjusted pre-tax profit guidance of £80 million to £90 million.

    Telecom Plus Operations

    Telecom Plus operates as Utility Warehouse and provides household services including energy, broadband, mobile and insurance.

    Customers can combine multiple services on a single monthly bill, with customer acquisition primarily conducted through the company’s nationwide partner network.

  • Kenmare Resources Confirms Non-Binding Cash Takeover Proposal From IRH

    Kenmare Resources Confirms Non-Binding Cash Takeover Proposal From IRH

    Kenmare Resources (LSE:KMR) has confirmed that it received a non-binding cash proposal from International Resources Holdings RSC Ltd for the entire issued and to be issued share capital of the company.

    The confirmation followed recent market speculation regarding a potential transaction.

    Kenmare said discussions with International Resources Holdings, or IRH, are ongoing. However, there is no certainty that the discussions will result in a firm offer or what the terms of any potential offer would be.

    IRH Faces 17 November Takeover Deadline

    Under the Irish Takeover Rules, IRH is required by 5:00 p.m. on 17 November 2026 either to announce a firm intention to make an offer for Kenmare or state that it does not intend to make an offer.

    The deadline may be extended with the consent of the Irish Takeover Panel in accordance with the applicable rules.

    The announcement also places Kenmare in an offer period, triggering disclosure requirements under the Irish Takeover Rules. Investors holding interests of 1% or more in relevant securities are subject to applicable dealing and position disclosure requirements during this period.

    Kenmare said the announcement also formally places previously unpublished inside information relating to the approach into the public domain.

    Kenmare Resources Operations

    Kenmare Resources is a mineral sands producer whose shares are listed on the London Stock Exchange and Euronext Dublin.

    The company has approximately 89.2 million ordinary shares in issue and also operates a restricted share option plan.

    No firm takeover offer has been announced, and the terms of any potential transaction remain subject to the outcome of discussions between Kenmare and IRH.

  • Georgina Energy Plans Mt Winter Site Work Ahead of Prospect Re-Entry

    Georgina Energy Plans Mt Winter Site Work Ahead of Prospect Re-Entry

    Georgina Energy PLC (LSE:GEX) is preparing to conduct site inspections at its Mt Winter helium, hydrogen and hydrocarbons prospect in Australia’s Amadeus Basin as it progresses plans for re-entry at the project.

    The company said inspections are scheduled to take place from 18 to 23 October and will cover civil engineering access, environmental assessments and the layout of a planned seismic programme.

    The work is intended to support preparations for prospect re-entry and future drilling activities at Mt Winter.

    Regulatory and Land Access Work Progresses

    Georgina said terms under the Aboriginal Land Rights Act have been agreed, while approvals from the Central Land Council and Traditional Owners are targeted for mid-November.

    Approval for the planned seismic programme is also expected shortly, according to the company.

    Georgina is separately progressing settlement of its acquisition of a 100% interest in EP155, which contains the Mt Winter prospect, and has begun preliminary discussions with drilling contractors.

    Chief executive Anthony Hamilton said the forthcoming inspection would support planning for civil works and environmental approvals ahead of potential drill rig mobilisation.

    Mt Winter Targets Helium, Hydrogen and Hydrocarbons

    Georgina has identified Mt Winter as prospective for helium, hydrogen and hydrocarbons based on its internal resource estimates. These remain estimates, and the supplied material does not establish that commercially recoverable resources have been demonstrated at the project.

    Mt Winter is located in the Amadeus Basin near the producing Mereenie Oil & Gas Field.

    The company is also advancing the Hussar prospect in Australia’s Officer Basin as part of its exploration and development portfolio.

    Georgina Energy Operations

    Georgina Energy is a London-listed helium, hydrogen and natural gas exploration and development company with onshore interests in Australia.

    Through subsidiary Westmarket O&G, the company holds a 100% interest in the Hussar prospect and is progressing towards a full working interest in Mt Winter.

    Its exploration strategy is focused on evaluating helium, hydrogen and gaseous hydrocarbon resources across the two projects.